Full Press Release Details
CARLSBAD, Calif.,Dec. 3, 2014/PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRxin patients with familial chylomicronemia syndrome (FCS) were published inThe New England Journal of Medicine.The paper, titled "Targeting ApoC-III in the Familial Chylomicronemia Syndrome" (Gaudetet al,N Engl J Med2014: 371:23: 2200-2206), show that patients with FCS treated with ISIS-APOCIIIRxachieved substantial reductions in apoC-III, triglycerides, chylomicrons and apoC-III-associated very low density lipoprotein-cholesterol (VLDL-C) particles. The three FCS patients in this open-label study had baseline triglyceride levels ranging from 1,406 mg/dL to 2,083 mg/dL and all three patients achieved triglyceride levels below 500 mg/dL during the study. FCS is a rare genetic disorder characterized by severe elevated levels of triglycerides. Current treatment options do not adequately reduce triglycerides and, as a result, patients with FCS have increased risk of recurrent and potentially fatal pancreatitis and other complications.
"These data, published today inThe New England Journal of Medicine, are a significant step in better understanding the mechanisms and treatment of a rare and very serious disorder of fat metabolism that is often associated with a number of serious health problems. Patients with FCS often have triglyceride levels that are higher than 2,000 mg/dL because they have a genetic defect affecting a key enzyme of fat management, lipoprotein lipase (LPL). FCS patients have extremely low levels of LPL activity and a significant reduction in the breakdown of triglycerides, which leads to extremely high triglyceride levels in circulation. ISIS-APOCIIIRxis designed to reduce apoC-III, which is known to regulate the LPL-dependent pathway. The data published today suggest, for the first time, that reducing levels of apoC-III results in marked reductions in triglycerides that are independent of LPL activity," said Daniel Gaudet, M.D., Ph.D., from the department of medicine, Universite deMontrealand scientific director of the Genome Quebec Biobank Technology Center. "Because of their genetic defect, patients with FCS have very limited therapeutic options and diet and lifestyle changes are not sufficient to significantly reduce their triglycerides. These data published today, although collected from a small number of patients, are compelling and demonstrate the potential of ISIS-APOCIIIRxto produce substantial triglyceride lowering in patients with FCS. They also suggest that apoC-III plays a critical role in fat management through a non-LPL dependent pathway, which would be a shift of paradigm."
The FCS patients in this study were treated with 300 mg of ISIS-APOCIIIRxas part of a Phase 2 open-label study that was designed to assess the safety and activity of ISIS-APOCIIIRxin patients with severely high triglycerides. All three FCS patients had a genetic confirmation of FCS, no detectable LPL activity and baseline triglyceride levels greater than 1,400 mg/dL.
Table 1: Substantial Reductions of Triglycerides and ApoC-III as a Single Agent Observed in a Phase 2 Study in ISIS-APOCIIIRx- treated Patients with FCS.
| Patient 1(485 mg/dL lowest TG)** | Patient 2(251 mg/dL lowest TG)** | Patient 3(234 mg/dL lowest TG)** | Mean %Change | |||||||
| Baseline(mg/dL) | Primary Endpoint (mg/dL) | * % Change | Baseline(mg/dL) | Primary Endpoint (mg/dL) | *% Change | Baseline(mg/dL) | Primary Endpoint (mg/dL) | *% Change | ||
| Triglycerides | 1406 | 616.5 | -56 | 2083 | 287.5 | -86 | 2043 | 734.5 | -64.0 | -69 |
| ApoC-III | 18.9 | 5.5 | -71 | 35.1 | 3.4 | -90 | 19.8 | 3.5 | -83 | -81 |
| VLDL-ApoC-III | 12.2 | 4.5 | -63 | 32.6 | 2.5 | -92 | 16.8 | 2.3 | -86 | -80 |
| HDL-C | 16 | 24 | +50 | 8 | 21 | +163 | 14 | 17 | +21 | +78 |
| Non-HDL-C | 214 | 114.5 | -46 | 327 | 84 | -74 | 244 | 111 | -55 | -58 |
Patient 1
(485 mg/dL lowest TG)**
Patient 2
(251 mg/dL lowest TG)**
Patient 3
(234 mg/dL lowest TG)**
Mean %
Change
Baseline
(mg/dL)
Primary Endpoint (mg/dL)
* % Change
Baseline
(mg/dL)
Primary Endpoint (mg/dL)
*% Change
Baseline
(mg/dL)
Primary Endpoint (mg/dL)
*% Change
Triglycerides
1406
616.5
-56
2083
287.5
-86
2043
734.5
-64.0
-69
ApoC-III
18.9
5.5
-71
35.1
3.4
-90
19.8
3.5
-83
-81
VLDL-ApoC-III
12.2
4.5
-63
32.6
2.5
-92
16.8
2.3
-86
-80
HDL-C
16
24
+50
8
21
+163
14
17
+21
+78
Non-HDL-C
214
114.5
-46
327
84
-74
244
111
-55
-58
| *Percent changes from baseline at primary endpoint (an average measurement of day 85 and 92) |
| ** Lowest triglyceride level achieved during study |
*Percent changes from baseline at primary endpoint (an average measurement of day 85 and 92)
** Lowest triglyceride level achieved during study
The safety and tolerability of ISIS-APOCIIIRxin patients with FCS to date supports continued development. The most common adverse event was injection site reactions, which were predominantly mild and typically resolved rapidly. There were no flu-like symptoms, no treatment-related elevations of liver enzymes greater than three times upper limit of normal, no abnormalities in renal function, no clinically meaningful changes in other laboratory values and no treatment-related serious adverse events.
"The data published today provides support for a novel mechanism by which reducing apoC-III promotes triglyceride clearance in patients with FCS and gives us a great deal of optimism as we enter Phase 3 development of ISIS-APOCIIIRx. In our Phase 2 studies, we showed that ISIS-APOCIIIRxlowered triglycerides equally well in patients with high to severely high triglycerides. We also observed dramatic reductions in apoC-III and other lipid parameters and we observed an increase in HDL-cholesterol," Dr.Sotirios Tsimikas, M.D., professor of medicine and director of vascular medicine at theUniversity of California, San Diegoand vice president of clinical development and leader of the cardiovascular franchise at Isis. "We believe that there is a significant unmet medical need for an effective triglyceride-lowering drug for patients with FCS. As such, we are encouraged with the robust results we have observed with ISIS-APOCIIIRxin FCS patients to date. We have initiated our registration-directed Phase 3 study of ISIS-APOCIIIRxin patients with FCS and plan to initiate a second Phase 3 study in patients with severely high triglycerides early next year."
FCS is a rare genetic disorder that affects approximately one to two out of a million people. The most common genetic cause of FCS is a defect in the lipoprotein lipase (LPL) gene, which results in extremely low levels of LPL activity and a significant reduction in the breakdown of triglycerides. In the study reported today, all three patients were homozygotes or compound heterozygotes for null LPL gene mutations resulting in undetectable LPL activity.
ISIS-APOCIIIRxis an antisense drug in development intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents. ISIS-APOCIIIRxis designed to target apoC-III, a protein produced in the liver that plays a central role in the regulation of serum triglycerides. Humans who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease. Humans with elevated levels of apoC-III have high triglycerides associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome. In addition, the prevalence of type 2 diabetes is increased in patients with elevated triglycerides. Humans with severely elevated levels of triglycerides are at risk of many serious health conditions, including pancreatitis, which can be life-threatening and require hospitalization.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 34 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, inthe United Statesand other countries for the treatment of patients with homozygous FH. Isis has numerous drugs in Phase 3 development in severe and rare and cardiovascular diseases. These include a ISIS-APOCIIIRx, a drug Isis is developing to treat patients with severely high triglycerides, such as patients with familial chylomicronemia syndrome; ISIS-TTRRx, a drug Isis is developing with GSK to treat patients with the polyneuropathy form of TTR amyloidosis; and, ISIS-SMNRx, a drug Isis is developing with Biogen Idec to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available atwww.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding the discovery, development, and potential of drugs for cardiovascular diseases, and the development, activity, therapeutic potential and safety of ISIS-APOCIIIRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year endedDecember 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals®is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO®is a registered trademark of Genzyme Corporation.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isis-apociii-rx-phase-2-study-in-patients-with-familial-chylomicronemia-published-in-the-new-england-journal-of-medicine-300004522.html